Quotient technology specializes in both Passive Immune Therapy and Hyper Immune Therapy. This is a process where the antibody from special donors are given to immune compromised patients when they cannot make the antibody they need themselves. Thus, Hyper Immune Therapy can both protect from infection and or control immune function.
Quotient’s insights and extensive know-how have allowed it to develop, generate and collect custom blends of powerful human antibodies with activity in specific disease indications. Central to this capability is Quotient’s identification and selection of specific donors, the immunization of those donors to produce large quantities of the desirable antibodies, and the separation and blending of those antibodies for specific end uses. This in turn, led Quotient to develop its current potentially breakthrough technology platform, trade secrets and proprietary know-how. After FDA approval, this platform technology may provide Quotient with the potential capability:
The Quotient Advantage
Human Physiology is Polyclonal: When the body responds correctly to an immunological threat, it produces a blend of specific antibodies with a diversity of capabilities (polyclonal) rather than just one (monoclonal). This is true even though the body may be confronting one disease state, because many disease indications are associated with multiple disease pathways.
Unparalleled safety. Human polyclonal antibodies are widely recognized and accepted by the FDA as safe for human use. This should allow Quotient to eliminate multiple costly and time-consuming safety trials, dramatically reducing the time and cost to market.
Antibody separation without degradation: Quotient has a proprietary method that specifically isolates the key “active ingredients” of polyvalent human antibody from the blood plasma, limiting the degradation associated with the fractionation process in commercial use today. This provides us with a substantially greater active product yield and efficacy, because the refined antibody itself has greater therapeutic effect.
Unlike conventional immune globulin products, which begin with low concentrations of ordinary antibodies that are further degraded during processing, Quotient’s technology produces large quantities of potent antibodies. The combination of quantity and potency, together with its proprietary separation technology and know-how that limits the degradation of antibody activity, gives Quotient the opportunity to make a commercially viable product that can be collected and processed to make millions of doses cost-effectively. We are currently collecting FDA approved “Source Plasma” containing antibodies for use in a variety of disease indications.
Quotient’s insights and extensive know-how have allowed it to develop, generate and collect custom blends of powerful human antibodies with activity in specific disease indications. Central to this capability is Quotient’s identification and selection of specific donors, the immunization of those donors to produce large quantities of the desirable antibodies, and the separation and blending of those antibodies for specific end uses. This in turn, led Quotient to develop its current potentially breakthrough technology platform, trade secrets and proprietary know-how. After FDA approval, this platform technology may provide Quotient with the potential capability:
- For allergy and allergic asthma, Quotient’s research is focused on “turning off” the body’s allergic and asthmatic response using a conceptually similar therapeutic approach used by RhoGAM (Anti-D), not just partially treating or “masking” the symptoms.
- Immune regulation and control across dozens of immune control functions simultaneously, normalizing immune function, down regulating inflammatory response, and helping “re-set” autoimmunity to normal levels.
The Quotient Advantage
Human Physiology is Polyclonal: When the body responds correctly to an immunological threat, it produces a blend of specific antibodies with a diversity of capabilities (polyclonal) rather than just one (monoclonal). This is true even though the body may be confronting one disease state, because many disease indications are associated with multiple disease pathways.
Unparalleled safety. Human polyclonal antibodies are widely recognized and accepted by the FDA as safe for human use. This should allow Quotient to eliminate multiple costly and time-consuming safety trials, dramatically reducing the time and cost to market.
Antibody separation without degradation: Quotient has a proprietary method that specifically isolates the key “active ingredients” of polyvalent human antibody from the blood plasma, limiting the degradation associated with the fractionation process in commercial use today. This provides us with a substantially greater active product yield and efficacy, because the refined antibody itself has greater therapeutic effect.
Unlike conventional immune globulin products, which begin with low concentrations of ordinary antibodies that are further degraded during processing, Quotient’s technology produces large quantities of potent antibodies. The combination of quantity and potency, together with its proprietary separation technology and know-how that limits the degradation of antibody activity, gives Quotient the opportunity to make a commercially viable product that can be collected and processed to make millions of doses cost-effectively. We are currently collecting FDA approved “Source Plasma” containing antibodies for use in a variety of disease indications.